Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. NICE technology appraisal guidance 813
National Institute for Health and Care Excellence (NICE)
Record ID 32018011855
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta813
Year Published:
2022
URL for published report:
https://www.nice.org.uk/guidance/ta813
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Tyrosine Kinase Inhibitors
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.